Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

36

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

36 results for “The VELOCE study”

Learn how ShareScore rates datasets ↗
zenodo36/100

GPS velocity field in the Pamir region in the Eurasian-fixed frame complied from our own results and previous studies

<p>The data file includes the GPS velocities with respect to the Eurasian frame in the Pamir, Tien Shan region.</p>

opencc-by-4.0Sep 2020View details →
ClinicalTrials.gov36/100

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

ClinicalTrials.gov study NCT04067011. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

VELOCITY: An Anthrax Vaccine Clinical Study

ClinicalTrials.gov study NCT03877926. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad32/100

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study

<p><b>Objective</b></p> <p><span>The phase IIIb VELOCE study (NCT02545868) assessed responses to selected vaccines in ocrelizumab (OCR)-treated patients with relapsing multiple sclerosis.</span></p> <p><b>Methods</b></p> <p>Patients were randomized 2:1 into Group OCR (n=68; OCR 600mg); or Control (n=34; interferon-β or no disease-modifying therapy). All received tetanus toxoid (TT)-containing vaccine, Pneumovax® (23-PPV) and keyhole limpet hemocyanin (KLH). Group OCR was subdivided into OCR1 (n=33) and OCR2 (n=35) at randomization. OCR1 received Prevnar® (13-PCV) 4 weeks after 23-PPV; OCR2 and Control received influenza vaccine. Vaccinations started 12 weeks after OCR initiation (Group OCR) or on Day 1 (Control).</p> <p><b>Results</b></p> <p>Positive response rate to TT vaccine at 8 weeks was 23.9% in OCR vs 54.5% in Control. Positive response rate to ≥5 serotypes in 23-PPV at 4 weeks was 71.6% in OCR and 100% in Control. Prevnar® did not enhance response to pneumococcal serotypes in common with Pneumovax®. Humoral response to KLH was decreased in OCR vs Control. Seroprotection rates at 4 weeks against five influenza strains ranged from 55.6–80.0% in OCR2 and 75.0–97.0% in Control.</p> <p><b>Conclusion</b></p> <p>Peripherally B-cell depleted OCR recipients mounted attenuated humoral responses to clinically relevant vaccines and the neoantigen, KLH, suggesting use of standard non-live vaccines while on OCR treatment remains a consideration. For seasonal influenza vaccines, it is recommended to vaccinate patients on OCR, as a potentially protective humoral response, even if attenuated, can be expected.</p>

opencc-zeroAug 2020View details →
zenodo32/100

The ambient noise cross-correlation function and teleseismic events, the Love-wave phase velocities, Rayleigh-wave phase and group velocities and H/V, Vsv and Vsh model in the study region (CNCC)

<p>The cross-correlation functions form EOBSArray (COR_CNCC), The Love-wave phase velocities (Love_phase), Rayleigh-wave phase (Rayleigh_phase) and group velocities (Rayleigh_group) and H/V (HtoV),and 3-D Vsv and Vsh model and related uncertainties (Vsv_Vsh_model) in the study region (CNCC) are archieved in the file named CNCC_data.7z.</p>

opencc-by-4.0May 2024View details →
zenodo32/100

Dataset for the study of "Seismic fault slip at depths simulated by high-velocity friction experiments under hydrothermal conditions"

<p>These are measured data of high-velocity friction experiments conducted on gabbro and marble under hydrothermal conditions (initial ambient temperature of 40 to 400 degC and pore pressure of 30 MPa).&nbsp;</p> <p>In each txt file, Column1 to Column9: Time (s), Slip Velocity (m/s), Displacement (m), Friction coefficient, Axial Displacement (mm), Pore water pressure (MPa), Effective normal stress (MPa), Sample Temperature (degC) and Furnace Temperature (degC).</p>

opencc-by-4.0Aug 2024View details →
ClinicalTrials.gov32/100

FIM-NL - First-in-Man Study (Netherlands Part) With Sirolimus Coated Modified BX Velocity Stent

ClinicalTrials.gov study NCT00233818. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

The Study of the BX VELOCITY Stent In Patients With De Novo Coronary Artery Lesions.

ClinicalTrials.gov study NCT00235144. IPD Sharing: Not stated. Countries: 1. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

FIM-BR - First-in-Man Study (Brazil Part) With Sirolimus-Coated BX VELOCITY Stent

ClinicalTrials.gov study NCT00233792. IPD Sharing: Not stated. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Alcohol Consumption and Arterial Stiffness: A Longitudinal Study of Pulse Wave Velocity in the Whitehall II Cohort

ClinicalTrials.gov study NCT02663791. IPD Sharing: YES. Countries: 1. Publications: 10.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions

ClinicalTrials.gov study NCT00489164. IPD Sharing: Not stated. Countries: 5. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

TCD Detection of Ophthalmic Artery Blood Flow Velocity Prediction Feasibility Study of Intracranial Pressure

ClinicalTrials.gov study NCT02240394. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)

ClinicalTrials.gov study NCT00232765. IPD Sharing: Not stated. Countries: 1. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Simplified Pulse Wave Velocity Measurement, Validation Study of the pOpmètre in Children

ClinicalTrials.gov study NCT02991703. IPD Sharing: Not stated. Countries: 0. Publications: 8.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad32/100

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study

Open the record for dataset details and reuse information.

publicAug 2020View details →
ClinicalTrials.gov28/100

The Study of the BX Velocity Stent in the Treatment of De Novo Artery Lesions.

ClinicalTrials.gov study NCT00381420. IPD Sharing: Not stated. Countries: 0. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

VELOCITY: A Study to Characterize Real-World Outcomes of Spinal Cord Stimulation

ClinicalTrials.gov study NCT02741297. IPD Sharing: NO. Countries: 4. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems

ClinicalTrials.gov study NCT00715884. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

ClinicalTrials.gov study NCT00449072. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
zenodo24/100

Effects of solar wind density and velocity variations on the Martian ionosphere and plasma transport—a MHD model study

<p>MHD simulation data for paper: Effects of solar wind density and velocity variations on the Martian ionosphere and plasma transport—a MHD model study</p>

opencc-by-4.0Nov 2023View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record